[
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Tesla, Nvidia, Amazon, Netflix, Discover, Salesforce, UnitedHealth, and More",
    "summary": "Tesla slides ahead of quarterly earnings scheduled for Tuesday, and Nvidia tumbles with the chip maker a victim of the U.S.-China trade war.",
    "url": "https://finnhub.io/api/news?id=5073bbc21efb63527dac0034371419b35b3f10e3f7faf22e28669d3ff58dd6f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745266860,
      "headline": "These Stocks Moved the Most Today: Tesla, Nvidia, Amazon, Netflix, Discover, Salesforce, UnitedHealth, and More",
      "id": 134031887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tesla slides ahead of quarterly earnings scheduled for Tuesday, and Nvidia tumbles with the chip maker a victim of the U.S.-China trade war.",
      "url": "https://finnhub.io/api/news?id=5073bbc21efb63527dac0034371419b35b3f10e3f7faf22e28669d3ff58dd6f0"
    }
  },
  {
    "ts": null,
    "headline": "5 Reasons To Buy Eli Lilly",
    "summary": "5 Reasons To Buy Eli Lilly",
    "url": "https://finnhub.io/api/news?id=a82af6756ab5bf3d7ed276ad103bc52ca12ba3ae83ccdf4d6e01efad1d905408",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745256440,
      "headline": "5 Reasons To Buy Eli Lilly",
      "id": 134027188,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a82af6756ab5bf3d7ed276ad103bc52ca12ba3ae83ccdf4d6e01efad1d905408"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): Among the Best American Dividend Stocks to Buy According to Analysts",
    "summary": "We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by delivering consistent and solid returns. During periods of […]",
    "url": "https://finnhub.io/api/news?id=56891f45ff0a5a36d2356236b5c422aaac42a4eb095d2f3d3039457f1aa12fbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745245320,
      "headline": "Eli Lilly and Company (LLY): Among the Best American Dividend Stocks to Buy According to Analysts",
      "id": 134022697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by delivering consistent and solid returns. During periods of […]",
      "url": "https://finnhub.io/api/news?id=56891f45ff0a5a36d2356236b5c422aaac42a4eb095d2f3d3039457f1aa12fbf"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Netflix, Tesla, Nvidia, Amazon, Discover, Salesforce, and More",
    "summary": "Netflix shares rise following better-than-expected earnings, and Tesla slides ahead of quarterly earnings scheduled for Tuesday.",
    "url": "https://finnhub.io/api/news?id=0b6de850f70f9ef6b69c4c78cde016e220ea1c9567c29bef8cff532f51b26fd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745243100,
      "headline": "These Stocks Are Moving the Most Today: Netflix, Tesla, Nvidia, Amazon, Discover, Salesforce, and More",
      "id": 134022688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Netflix shares rise following better-than-expected earnings, and Tesla slides ahead of quarterly earnings scheduled for Tuesday.",
      "url": "https://finnhub.io/api/news?id=0b6de850f70f9ef6b69c4c78cde016e220ea1c9567c29bef8cff532f51b26fd7"
    }
  },
  {
    "ts": null,
    "headline": "Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?",
    "summary": "Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.  Is it time to buy the dip in Novo Nordisk stock?  With a history dating back more than 100 years, Novo Nordisk has long been a leader in diabetes care.",
    "url": "https://finnhub.io/api/news?id=55e451100f40f1542f89aac882fa8a5cf6aef0f2ab89e25755462ae57bfdb9c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745241300,
      "headline": "Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?",
      "id": 134022699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.  Is it time to buy the dip in Novo Nordisk stock?  With a history dating back more than 100 years, Novo Nordisk has long been a leader in diabetes care.",
      "url": "https://finnhub.io/api/news?id=55e451100f40f1542f89aac882fa8a5cf6aef0f2ab89e25755462ae57bfdb9c2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=1d7698c5ee5939e116c4fb2b6c519871e943da229e3d16c1fe39a87bc71db87e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745240416,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 134022700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=1d7698c5ee5939e116c4fb2b6c519871e943da229e3d16c1fe39a87bc71db87e"
    }
  },
  {
    "ts": null,
    "headline": "LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study",
    "summary": "Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.",
    "url": "https://finnhub.io/api/news?id=7e736e0a12317e52a309b7187f6e2111baa6ce2ba1211a283f1da6775f2c6d18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745239020,
      "headline": "LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study",
      "id": 134022701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.",
      "url": "https://finnhub.io/api/news?id=7e736e0a12317e52a309b7187f6e2111baa6ce2ba1211a283f1da6775f2c6d18"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges",
    "summary": "Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.",
    "url": "https://finnhub.io/api/news?id=9a20818799793acc9d6b1ad78bb82e46f98a1554205d2ce0043b79d42920e8dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745238600,
      "headline": "Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges",
      "id": 134022702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.",
      "url": "https://finnhub.io/api/news?id=9a20818799793acc9d6b1ad78bb82e46f98a1554205d2ce0043b79d42920e8dd"
    }
  },
  {
    "ts": null,
    "headline": "Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?",
    "summary": "Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.",
    "url": "https://finnhub.io/api/news?id=a0648967224c1890fb62eb4ca443a0d039625a860e61007eb1dcffbc8bbed606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745237820,
      "headline": "Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?",
      "id": 134022703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.",
      "url": "https://finnhub.io/api/news?id=a0648967224c1890fb62eb4ca443a0d039625a860e61007eb1dcffbc8bbed606"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Just Say Checkmate to Novo Nordisk?",
    "summary": "Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight.  The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.  It soon was joined by Eli Lilly (NYSE: LLY), selling similar drugs -- the molecule tirzepatide, approved in 2022 under the name Mounjaro for the diabetes indication and approved a year later as Zepbound for weight loss.",
    "url": "https://finnhub.io/api/news?id=540f927fbe28184444d25e1659fcd04e61792fb4fc423f8d8e4b0245d85f360f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745224200,
      "headline": "Did Eli Lilly Just Say Checkmate to Novo Nordisk?",
      "id": 134022704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight.  The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.  It soon was joined by Eli Lilly (NYSE: LLY), selling similar drugs -- the molecule tirzepatide, approved in 2022 under the name Mounjaro for the diabetes indication and approved a year later as Zepbound for weight loss.",
      "url": "https://finnhub.io/api/news?id=540f927fbe28184444d25e1659fcd04e61792fb4fc423f8d8e4b0245d85f360f"
    }
  },
  {
    "ts": null,
    "headline": "Can anything threaten Novo and Lilly’s obesity market dominance?",
    "summary": "Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.",
    "url": "https://finnhub.io/api/news?id=3bacaa89f833db7d874d8dca8d3df4f50a3541a1ac7b55dffe483ae4fa629543",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745222400,
      "headline": "Can anything threaten Novo and Lilly’s obesity market dominance?",
      "id": 134022705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.",
      "url": "https://finnhub.io/api/news?id=3bacaa89f833db7d874d8dca8d3df4f50a3541a1ac7b55dffe483ae4fa629543"
    }
  }
]